Continuous breakthroughs in the field of life sciences are leading a new round of scientific and technological revolution and industrial transformation. Looking at the world, China's pharmaceutical and health industry has a broad market and active innovation. Beijing GoBroad Central Laboratory is positioned as an international research hospital and actively builds a public service platform for clinical research in Beijing. In order to better learn from the advanced experience and concept of international research hospitals and promote collaborative innovation from all walks of life in the industry, 2023 Beijing · Changping Life Science International Forum · Go Broad Science Forum was held in Beijing from July 29 to 30, 2023.
Dr. Hongjiu Dai, founder, executive president and chairman of KAEDI, was invited to attend the 2023 Beijing Changping International Life Science Forum GoBroad Science Forum, and participate in the roundtable discussion of "Solid Tumor Research Innovation and Transformation Forum" on July 30, deeply discussing the innovation and development of solid tumor research with the participating experts. Dr. Hongjiu Dai focused on KAEDI development of dual-targeted autologous and allogeneic CAR-T new drugs in solid tumors. KAEDI is a clinical-stage biopharmaceutical company focused on the development of immune cell therapies for tumor diseases, focusing on CAR-T and CAR-NK therapy for solid tumors. Leveraging the world's leading synthetic biotechnology platforms KD-SmCAR™ and KD-ScCAR™, the company has successfully developed a number of innovative cell therapies for malignant tumors, including autologous and allogeneic CAR-T, three of which have entered the clinical stage. Preclinical results of one of the core pipelines, KD-025 CAR-T, have been published in several international journals. Including "Journal for Immunotherapy of Cancer","Cancer Immunology Research" and "Cancer Science". The early KD-025 CAR-T IIT clinical trial has completed a number of low-dose administration cases, who no obvious toxic and side effects, the product is safe and effective, the pipeline has obtained the IND clinical approval of CDE, and is currently planning to start the registration of phase I clinical with a number of cooperative units. The research and development results of KAEDI in CAR-T therapy provide a new direction for the treatment of malignant tumors, so that people are full of expectations for anti-cancer immunotherapy. The research and development results not only highlight the impact of innovation and technology on human health, but also make us optimistic about the future of medical technology. We are full of expectations for the future development of KAEDI and firmly believe that it will make greater contributions to human life and health.
About KAEDI
KAEDI is a clinical stage drug discovery and development company that uses a leading synthetic biology technology platform to develop novel cellular drugs for the clinically unmet needs of solid tumor patients. Leveraging our own CAR library screening platform, KD-SmCAR™ , and dual targeting CAR development platform, KD-ScCAR™, we have successfully developed a number of new cellular drug pipelines for solid tumors, including next-generation autologous and allogeneic CAR-T pipelines. At present, we have applied for more than 30 CAR-related patents in China and the United States, and obtained 15 authorized patents, among which the core pipeline KD-025, KD-496 patents are the first authorized in China and the United States.
The development results of KD-025 CAR-T products targeting NKG2DL for liver cancer, colorectal cancer and glioma have successively been published in the international authoritative Journal of tumor ImmunoTherapy "Journal for ImmunoTherapy of Cancer", "Cancer Immunology Research", Research and ASCO, the American Cancer Clinical Annual meeting. The KD-025 CAR-T IIT clinical trial carried out earlier in well-known clinical centers in China has completed many cases of low-dose administration, who no obvious toxic and side effects, and the product is safe and effective. It is the first domestic CAR-T (KD-025) cell injection IND application for NKG2DL solid tumor was approved by CDE clinical company. At present, we are negotiating with a number of cooperative units to start KD-025registration phase I clinical, at the same time,the company's core product KD-496 entered the IIT clinical stage as the world's first new dual-targeted CAR-T cell injection. In addition, KAEDI is promoting the layout of the next generation of new CAR-T and allogeneic universal CAR, which is expected to build KAEDI Medical into a global well-known company for solid tumor cell therapy in the near future.